Relief Therapeutics’ RLF-TD011 Faces Setback with FDA Decision

RELIEF THERAPEUTICS Holding ( (CH:RLF) ) has shared an update.

Relief Therapeutics announced that the FDA did not grant Qualified Infectious Disease Product designation for its investigational therapy RLF-TD011 for epidermolysis bullosa. Despite this, the company maintains its development strategy, supported by Orphan Drug and Rare Pediatric Disease designations, which offer regulatory and commercial incentives. The company continues to progress with the FDA on advancing RLF-TD011 into later-stage development, highlighting its commitment to addressing unmet needs in EB care.

More about RELIEF THERAPEUTICS Holding

Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company based in Geneva, focused on developing innovative treatments for rare and debilitating diseases. The company specializes in drug delivery systems and drug repurposing, with a clinical pipeline targeting unmet medical needs in dermatological, metabolic, and respiratory conditions. Relief has successfully marketed several products through licensing and distribution partnerships.

Average Trading Volume: 41,860

Current Market Cap: CHF28.67M

For a thorough assessment of RLF stock, go to TipRanks’ Stock Analysis page.